Genomes and Genes
Affiliation: National Institutes of Health
- Drug targeting by long-circulating liposomal glucocorticosteroids increases therapeutic efficacy in a model of multiple sclerosisJens Schmidt
National Institute of Neurological Disorders and Stroke, Neuromuscular Diseases Section, National Institutes of Health, Building 10, Room 4N 248, 10 Center Drive MSC 1382, Bethesda, MD 20892, USA
Brain 126:1895-904. 2003..These findings may have implications for future therapy of autoimmune disorders such as multiple sclerosis...
- Intravenous liposomal prednisolone downregulates in situ TNF-alpha production by T-cells in experimental autoimmune encephalomyelitisJens Schmidt
Department of Neurology, University of Wurzburg, Wurzburg, Germany
J Histochem Cytochem 51:1241-4. 2003..Our results help to further understand mechanisms of action of drug targeting by liposomal steroids, with possible implications for treatment of autoimmune disorders such as MS...
- Selective targeting of regulatory T cells with CD28 superagonists allows effective therapy of experimental autoimmune encephalomyelitisNiklas Beyersdorf
Institute for Virology and Immunobiology, University of Wurzburg, D 97078 Wurzburg, Germany
J Exp Med 202:445-55. 2005..Our data indicate that this class of CD28-specific monoclonal antibodies targets CD4+CD25+ T reg cells and provides a novel means for the effective treatment of multiple sclerosis and other autoimmune diseases...
- Disease progression after bone marrow transplantation in a model of multiple sclerosis is associated with chronic microglial and glial progenitor responseRiccardo Cassiani-Ingoni
Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA
J Neuropathol Exp Neurol 66:637-49. 2007..Our data indicate that reactivation of a local inflammatory process after BMT is sustained predominantly by endogenous microglia/macrophages...
- Nitric oxide stress in sporadic inclusion body myositis muscle fibres: inhibition of inducible nitric oxide synthase prevents interleukin-1β-induced accumulation of β-amyloid and cell deathJens Schmidt
Department of Neurology, University Medical Centre Göttingen, Robert Koch Str 40, 37075 Gottingen, Germany
Brain 135:1102-14. 2012..The data further our understanding of the pathology of sporadic inclusion body myositis and may point to novel treatment strategies...
- Interrelation of inflammation and APP in sIBM: IL-1 beta induces accumulation of beta-amyloid in skeletal muscleJens Schmidt
Neuromuscular Diseases Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA
Brain 131:1228-40. 2008..The observations may help to design targeted treatment strategies for chronic inflammatory disorders of the skeletal muscle...
- Motor performance of young dystrophic mdx mice treated with long-circulating prednisolone liposomesCharlotte Weller
Department of Neurology, University Medical Center Gottingen, Gottingen, Germany
J Neurosci Res 90:1067-77. 2012..Our study helps to improve the future design of experimental treatment in animal models of neuromuscular diseases...
- Upregulation of thrombospondin-1(TSP-1) and its binding partners, CD36 and CD47, in sporadic inclusion body myositisMohammad Salajegheh
The Division of Neuromuscular Disease, Department of Neurology, Brigham and Women s Hospital, 75 Francis Street, Tower 5D, Boston, MA 02115, USA
J Neuroimmunol 187:166-74. 2007..The TSP-complex is another inflammatory mediator associated with chronic inflammation in IBM that may perpetuate the immune responses to local antigens in response to TNF-alpha...
- Provision of an explanation for the inefficacy of immunotherapy in sporadic inclusion body myositis: quantitative assessment of inflammation and β-amyloid in the muscleJana Zschüntzsch
University Medical Centre, Gottingen, Germany
Arthritis Rheum 64:4094-103. 2012..We undertook this study to determine why intravenous immunoglobulin (IVIG) and prednisone are not effective in sporadic IBM despite their effectiveness in other inflammatory myopathies...
- Treatment and prevention of experimental autoimmune neuritis with superagonistic CD28-specific monoclonal antibodiesJens Schmidt
Department of Neurology, University of Wurzburg, Josef Schneider Str 11, D 97080, Wurzburg, Germany
J Neuroimmunol 140:143-52. 2003..We demonstrate preventive and therapeutic effects of a "superagonistic" mAb-mediated, TCR-independent CD28 stimulation in EAN, possibly with implications for therapy of autoimmune-inflammatory disorders...
- Cell stress molecules in the skeletal muscle of GNE myopathyCharlotte Fischer
Department of Neurology, University Medical Center, Gottingen, Germany
BMC Neurol 13:24. 2013..In sporadic inclusion body myositis (sIBM), the pro-inflammatory cell-stress mediators αB-crystallin and inducible nitric oxide synthase (iNOS) are crucial markers of the disease pathology...
- Update on treatment of inclusion body myositisMaren Breithaupt
Department of Neurology, University Medical Centre Göttingen, Robert Koch Str 40, 37075, Gottingen, Germany
Curr Rheumatol Rep 15:329. 2013..Different treatment studies with drugs that aim at degenerative disease mechanisms are planned or ongoing. This review aims to provide an overview of the current treatment options for IBM...
- Role of interleukin 10 during persistent infection with the relapsing fever Spirochete Borrelia turicataeHarald Gelderblom
Cellular Immunology Section, Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, Clinical Studies Unit, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
Am J Pathol 170:251-62. 2007..IL-10 injected systemically reduced disease and spirochetemia. The results suggest IL-10 plays a protective role as a down-regulator of inflammation and pathogen load during infection with relapsing fever spirochetes...
- Upregulated inducible co-stimulator (ICOS) and ICOS-ligand in inclusion body myositis muscle: significance for CD8+ T cell cytotoxicityJens Schmidt
Neuromuscular Diseases Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892, USA
Brain 127:1182-90. 2004..The observations strengthen the immunopathogenesis of sIBM, and offer the basis for future therapeutic interventions targeting ICOS.ICOS-L co-stimulatory interactions...
- Liposomal glucocorticosteroids in treatment of chronic autoimmune demyelination: long-term protective effects and enhanced efficacy of methylprednisolone formulationsRalf A Linker
Department of Neurology at St Josef Hospital Ruhr University Bochum, Gudrunstrasse 56, D 44791 Bochum, Germany
Exp Neurol 211:397-406. 2008..These findings lay the groundwork for applying liposomal GS in clinical MS trials in the near future...
- Macroautophagy as a pathomechanism in sporadic inclusion body myositisJan D Lunemann
Laboratory of Viral Immunobiology, Christopher H Browne Center for Immunology and Immune Diseases, The Rockefeller University, New York, New York 10021, USA
Autophagy 3:384-6. 2007..A better understanding of this pathway in skeletal muscle and in the inflammatory environment of sIBM might provide a rationale for novel therapeutic strategies targeting pathogenic protein aggregation...